{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:58:46Z","timestamp":1792853926561,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T11:33:35Z","timestamp":1722425615000},"page":"347-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium"],"prefix":"10.1016","volume":"8","author":[{"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Sahrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaron","family":"Arbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lui Shiong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pavlovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H.","family":"Bangma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.07.006_b0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0094-0143(21)01377-X","article-title":"The case for no initial treatment of localized prostate cancer","volume":"17","author":"Smith","year":"1990","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2024.07.006_b0010","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","article-title":"Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression","volume":"167","author":"Choo","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0030","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0035","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-term outcomes of active surveillance for prostate cancer: the Memorial Sloan Kettering Cancer Center experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0040","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","article-title":"The long-term risks of metastases in men on, active surveillance for early stage prostate cancer","volume":"204","author":"Maggi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.juro.2015.08.087","article-title":"Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort","volume":"195","author":"Newcomb","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41467-021-27889-y","article-title":"Age influences on the molecular presentation of tumours","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2024.07.006_b0055","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 3.2024. Plymouth Meeting, PA: NCCN; 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.euo.2024.07.006_b0060","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2024. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"10.1016\/j.euo.2024.07.006_b0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euo.2019.08.014","article-title":"Adherence to active surveillance protocols for low-risk prostate cancer: results of the Movember Foundation\u2019s Global Action Plan prostate cancer active surveillance initiative","volume":"3","author":"Kalapara","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2021.11.006","volume":"35","author":"Olivier","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.07.006_b0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.euo.2024.07.006_b0080","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2024.07.006_b0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12859-019-2610-2","article-title":"BPG: seamless, automated and interactive visualization of scientific data","volume":"20","author":"P\u2019ng","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.euo.2024.07.006_b0090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.juro.2013.08.088","article-title":"The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance","volume":"191","author":"Ehdaie","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bju.13410","article-title":"Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study","volume":"118","author":"Bokhorst","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.07.006_b0100","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s10147-020-01761-3","article-title":"The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study","volume":"25","author":"Tohi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","article-title":"How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States","volume":"196","author":"Loeb","year":"2016","journal-title":"J Urol."},{"key":"10.1016\/j.euo.2024.07.006_b0110","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.euo.2019.05.005","article-title":"Intensity of active surveillance and transition to treatment in men with low-risk prostate cancer","volume":"3","author":"Olsson","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.eururo.2017.07.018","article-title":"Active surveillance versus watchful waiting for localized prostate cancer: a model to inform decisions","volume":"72","author":"Loeb","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0120","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.10.031","article-title":"Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer","volume":"72","author":"Van Hemelrijck","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.euf.2021.07.003","article-title":"Using competing risk of mortality to inform the transition from prostate cancer active surveillance to watchful waiting","volume":"8","author":"Huang","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.07.006_b0130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.07.006_b0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.eururo.2011.07.041","article-title":"The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance","volume":"61","author":"Ploussard","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.07.006_b0140","doi-asserted-by":"crossref","first-page":"201.e1","DOI":"10.1016\/j.urolonc.2015.02.004","article-title":"Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance","volume":"33","author":"de Cobelli","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.07.006_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bju.15136","article-title":"Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance","volume":"127","author":"Tomer","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.07.006_b0150","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease","volume":"280","author":"Ornish","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.07.006_b0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.urology.2008.04.050","article-title":"Clinical events in prostate cancer lifestyle trial: results from two years of follow-up","volume":"72","author":"Frattaroli","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.07.006_b0160","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41391-021-00343-2","article-title":"What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study","volume":"24","author":"Luiting","year":"2021","journal-title":"Prostate Cancer Prostat Dis"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:51:11Z","timestamp":1744883471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124001792"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.07.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}